LUDWIG INSTITUTE FOR CANCER RESEARCH





JAK mutations resistant to

ATP-competitive JAK inhibitors

L. Knoops



IL-9 R signal transduction



IL-9 R phe116 receptor





BaF3 phe116





In vitro model of tumorigenesis



In vitro model of tumorigenesis



JAK1 activating mutations



JAK1 activating mutations



JAK1 activating mutations



Schematic and 3D modeling of JAK1 structure

JAK1 activating mutations : kinase domain



JAK1 F958V is resistant to JAK inhibitor I





JAK1 F958V is resistant to INC424



JAK1 and ABL1 hinge regions



JAK1 and ABL1 hinge regions





JAK1, CP-690,500 (PDB 3EYG)



ABL1, Imatinib (PDB 2HYY)

JAK1 and ABL1 hinge regions





The JAK2 Y931C mutation - autonomous proliferation



Days without IL-3

The JAK2 Y931C mutation - autonomous proliferation



Days without IL-3

The JAK2 Y931C mutation - autonomous proliferation



Days without IL-3

The JAK2 Y931C mutation - INC424 response



INCB018424 (uM)

The JAK2 Y931C mutation - INC424 response



INCB018424 (uM)

The JAK2 Y931C mutation - INC424 response



INCB018424 (uM)



